Review Of Pfizer’s Maraviroc Will Reflect CCR5 Antagonist Class Safety Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Antiviral Drugs Advisory Committee will also assess whether existing data supports accelerated approval for the first-in-class HIV therapy.